Introduction
NSCLC, tumor, ALK-positive NSCLC, anaplastic lymphoma, ALK-positive non-small-cell lung cancer, treatment-naive advanced
TUMOR, NSCLC
Alectinib is a highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Alectinib is a preferred first-line therapy for patients with advanced ALK-positive non-small-cell lung cancer (NSCLC) [In recent years, the use of tumor dynamic modeling to support drug development and early decisions has significantly increased by drug developers and regulatory agencies [The objective of our analysis was to externally validate this framework to simulate OS and more specifically alectinib vs. crizotinib treatment effect (OS HR) in patients with treatment-naive advanced ALK-positive NSCLC in the alectinib ALEX study [